CSL Ltd
OTC:CSLLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Diamond Hill Investment Group Inc
NASDAQ:DHIL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (25.9), the stock would be worth $47.69 (97% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.1 | $24.16 |
0%
|
| 3-Year Average | 25.9 | $47.69 |
+97%
|
| 5-Year Average | 28.1 | $51.57 |
+113%
|
| Industry Average | 10.6 | $19.58 |
-19%
|
| Country Average | 16.8 | $30.89 |
+28%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$81.4B
|
/ |
Jan 2026
$4B
|
= |
|
|
$81.4B
|
/ |
Jun 2026
$4.9B
|
= |
|
|
$81.4B
|
/ |
Jun 2027
$5.1B
|
= |
|
|
$81.4B
|
/ |
Jun 2028
$5.4B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
CSL Ltd
OTC:CSLLY
|
66.1B USD | 13.1 | 30.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 20 | 86.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 15 | 19.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 22 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 42.2 | 38.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.8B USD | 80.5 | 130.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.7 |
| Median | 16.8 |
| 70th Percentile | 24.5 |
| Max | 6 797.5 |
Other Multiples
CSL Ltd
Glance View
In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.
